In Brief: Myriad Genetics Laboratories
This article was originally published in The Gray Sheet
Myriad Genetics Laboratories: Begins long-term study with the American College of Surgeons to evaluate outcomes of patients undergoing BRCA1 genetic analysis for breast and ovarian cancer susceptibility. The ACS-Myriad BRCA1 Longitudinal Study (AMBLS) will use Myriad's BRACAone genetic analysis test, which is slated for full commercial launch later this year ("The Gray Sheet" July 22, In Brief), and the firm's "multi-center, patient database to obtain mutation incidence and clinical data." The "major questions" to be addressed by the study include: "which BRCA1 mutations are strongly penetrant (have a strong correlation to the risk of getting the disease); and what is the likely clinical outcome after medical and surgical intervention"...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.